 PAVmed Inc. Nasdaq: PAVM, PAVMZ the Company or PAVmed, a highly differentiated, multiproduct medical device company, today announced the U.S. Food and Drug Administration FDA has acknowledged receipt of a 510k premarket notification submission for the Companys CarpXTM minimally invasive carpal tunnel device. This re-submission incorporates data from the Companys successful first-in-human CarpX clinical safety study, in which all patients met the studys pre-specified safety and effectiveness endpoints. We look forward to completing the U.S. regulatory process for CarpX so we can begin offering this groundbreaking technology for alleviating carpal tunnel syndrome to physicians and their patients, said Lishan Aklog, M.D., PAVmeds Chairman and Chief Executive Officer. 